2026-01-04 - Analysis Report
Okay, here's a comprehensive analysis of Hims & Hers Health Inc. (HIMS) based on the data you provided.

**0) Overview & Instructions:**

*   This report analyzes HIMS stock, comparing it to the S&P 500 (VOO).
*   It reviews return rates, technical indicators, news, analyst opinions, and financials to provide a comprehensive overview.

**1) Return Rate Comparison & Analysis:**

*   **Ticker:** HIMS
*   **Company Overview:** Hims & Hers Health Inc. is a telehealth company that offers personalized health and wellness solutions.
*   **Cumulative Return (HIMS):** 114.24%
*   **Cumulative Return (VOO):** 69.64%
*   **Divergence:** 39.6 (Relative Divergence: 30.1)

    *   HIMS has significantly outperformed the S&P 500 (VOO) in cumulative return.
    *   The divergence of 39.6 indicates HIMS's outperformance.  The relative divergence of 30.1 suggests this outperformance is relatively closer to the lower end of its historical divergence range compared to VOO. This indicates that while HIMS is still outperforming, it's not at its peak relative outperformance compared to the comparison stock, within the context of its past performance.
*   **Alpha, Beta Analysis:**

    | Year       | CAGR    | MDD  | Alpha  | Beta | Cap(B) |
    |------------|---------|------|--------|------|--------|
    | 2020-2022  | -19.0%  | 67.1% | -17.0% | 0.7  | 1.5    |
    | 2021-2023  | -65.0%  | 67.1% | -66.0% | 1.6  | 2.0    |
    | 2022-2024  | 119.0%  | 42.0% | 99.0% | 1.7  | 5.5    |
    | 2023-2025  | 114.0%  | 57.5% | 52.0% | 2.1  | 7.4    |

    *   **CAGR:** HIMS has experienced volatile growth, with negative CAGR in 2020-2022 and 2021-2023, followed by significant positive growth in 2022-2024 and 2023-2025.
    *   **MDD:** Maximum Drawdown indicates high risk, with MDD ranging from 42.0% to 67.1%, suggesting significant price volatility.
    *   **Alpha:**  Alpha consistently shows positive values in recent periods (2022-2024 and 2023-2025), meaning HIMS outperforms its benchmark index.
    *   **Beta:** Beta has increased over time, reaching 2.1, suggesting that HIMS is becoming more sensitive to market movements, and is more volatile than the market (S&P 500).
    *   **Cap(B):**  Market capitalization has increased, suggesting growing investor confidence.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 33.41
*   **Previous Close:** 32.47
*   **Change:** 2.89%
*   **5-day SMA:** 33.466
*   **20-day SMA:** 36.064
*   **60-day SMA:** 41.5878

    *   The stock price has increased slightly compared to the previous close.
    *   The 5-day SMA is close to the current price, while the 20-day and 60-day SMAs are higher, indicating a potential short-term upward trend but overall downward trend in the recent months.

**3) Technical Indicator Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 25.88 (Oversold)
*   **PPO:** -0.3306
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (26 shares - Very Safe - MRI:0.90) Monthly invest 1.3% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) relative divergence change:** -3.3 (Negative indicates short-term decline)
*   **Expected Return (%):** 47.9 (Expected excess return compared to S&P 500 if invested long-term)

    *   The MRI suggests a medium level of investment risk.
    *   The RSI indicates that the stock is currently oversold, potentially signaling a buying opportunity.
    *   The PPO is slightly negative.
    *   The hybrid signal recommends a 100% cash allocation to buying HIMS stock, suggesting a bullish outlook with a "Very Safe" rating.
    *   The negative divergence change indicates a recent short-term downward trend.
    *   The expected return of 47.9% is promising, suggesting significant potential for long-term investors.

**4) Recent News & Significant Events:**

*   **Recent negative articles:** Multiple recent articles highlight concerns including a losing spree, falling stock, and valuation concerns.
*   **Share Repurchase Program:** Announcement of a share repurchase program indicates company confidence in its value.
*   **Valuation Pullback:** An article discusses a valuation pullback, which might present an opportunity.

**4-2) Analyst Opinions:**

*   **Opinions:** 12 analysts covering the stock.
*   **Target Price (avg/high/low):** 44.67 / 85.00 / 25.00
*   **Target Price Analysis:** Average target price suggests potential upside, but there is a wide range of opinions.
*   **Recent Rating Changes:**  (No specific details provided in the input data)

**5) Recent Earnings Analysis:**

| 날짜       | EPS  | 매출      |
|------------|------|-----------|
| 2025-11-03 | 0.07 | 0.60 B$  |
| 2025-08-04 | 0.19 | 0.54 B$  |
| 2025-05-05 | 0.22 | 0.59 B$  |
| 2024-11-04 | 0.35 | 0.40 B$  |
| 2025-11-03 | 0.35 | 0.40 B$  |

*Note: It looks like there's a duplicated entry in your table.*

*   **EPS:** EPS has varied significantly, and has recently decreased.
*   **Revenue:** Revenue has generally increased over the past quarters, but seems to have plateaued around 0.60B$.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $0.60B     | 73.80%        |
| 2025-06-30   | $0.54B     | 76.39%        |
| 2025-03-31   | $0.59B     | 73.50%        |
| 2024-12-31   | $0.48B     | 76.81%        |
| 2024-09-30   | $0.40B     | 79.16%        |

*   **Revenue:** Revenue shows a growth trend over the past few quarters.
*   **Profit Margin:** Profit margins remain high, indicating strong operational efficiency.

**Capital and Profitability:**

| Quarter      | Equity     | ROE      |
|--------------|------------|----------|
| 2025-09-30   | $0.58B     | 2.72%   |
| 2025-06-30   | $0.56B     | 7.55%    |
| 2025-03-31   | $0.55B     | 9.01%    |
| 2024-12-31   | $0.48B     | 5.46%    |
| 2024-09-30   | $0.44B     | 17.18%   |

*   **Equity:** Equity has consistently increased, reflecting the company's growing value.
*   **ROE:** ROE has been volatile, with a significant drop in the most recent quarter.

**7) Comprehensive Analysis (Summary):**

*   **Strong Outperformance with Volatility:** HIMS has significantly outperformed the S&P 500 but exhibits high volatility and drawdown.
*   **Mixed Signals:** Technical indicators show an oversold condition (RSI) and a bullish investment signal. However, recent news and divergence changes point to short-term concerns.
*   **Strong Revenue Growth:** Revenue is growing, and profit margins remain high, but EPS and ROE have shown a recent decline.
*   **Analyst Uncertainty:** Analyst target prices suggest potential upside but with a wide range, reflecting differing opinions on the company's future.
*   **Key Considerations:**
    *   **Risk Tolerance:** HIMS appears to be a high-risk, high-reward investment.
    *   **Long-Term Potential:** The company has strong long-term growth potential given its leading technology and ability to provide services to the mass population. The Expected Return of 47.9% compared to S&P500, reinforces this outlook.
    *   **Recent Negative Momentum:** Recent negative news sentiment and short-term price declines should be considered.

**Conclusion:**

Hims & Hers Health presents a compelling investment case due to its high growth potential and outperformance relative to the S&P 500. However, investors should be aware of the company's high volatility, recent negative price momentum, and mixed analyst sentiment. A long-term investment strategy, with careful monitoring of the company's financial performance and market conditions, may be appropriate. The share repurchase program and high expected return compared to S&P 500 are encouraging signs.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.